Department of Ophthalmology, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, China
Department of Ophthalmology, Hong Kong Sanatorium and Hospital, Hong Kong, China.
Diabetes Care. 2020 Dec;43(12):2959-2966. doi: 10.2337/dc17-2612. Epub 2020 Oct 1.
To compare four screening strategies for diabetic macular edema (DME).
Patients attending diabetic retinopathy screening were recruited and received macular optical coherence tomography (OCT), in addition to visual acuity (VA) and fundus photography (FP) assessments, as part of the standard protocol. Two retina specialists provided the reference grading by independently assessing each subject's screened data for DME. The current standard protocol (strategy A) was compared for sensitivity, specificity, quality-adjusted life-year (QALY) gained, and incremental cost-effectiveness ratio (ICER) with three alternative candidate protocols using a simulation model with the same subjects. In strategy B, macular hemorrhage or microaneurysm on FP were removed as surrogate markers for possible DME. Strategy C used best-corrected instead of habitual/pinhole VA and added central subfield thickness (CST) >290 μm on OCT in suspected cases as a confirmation marker for possible DME. Strategy D used CST >290 μm OCT in all subjects as a surrogate marker for suspected DME.
We recruited 2,277 subjects (mean age 62.80 ± 11.75 years, 43.7% male). The sensitivities and specificities were 40.95% and 86.60%, 22.86% and 95.63%, 32.38% and 100%, and 74.47% and 98.34% for strategies A, B, C, and D, respectively. The costs (in U.S. dollars) of each QALY gained for strategies A, B, C, and D were $7,447.50, $8,428.70, $5,992.30, and $4,113.50, respectively.
The high false-positive rate of the current protocol generates unnecessary referrals, which are inconvenient for patients and costly for society. Incorporating universal OCT for screening DME can reduce false-positive results by eightfold, while improving sensitivity and long-term cost-effectiveness.
比较四种糖尿病性黄斑水肿(DME)筛查策略。
招募参加糖尿病视网膜病变筛查的患者,并在标准方案中除视力(VA)和眼底照相(FP)评估外,还接受黄斑光学相干断层扫描(OCT)检查。两名视网膜专家通过独立评估每个受检者筛查数据中的 DME,提供参考分级。通过对相同受试者使用模拟模型,将当前标准方案(策略 A)与三种替代候选方案(策略 B、策略 C 和策略 D)进行比较,比较敏感度、特异度、质量调整生命年(QALY)增益和增量成本效益比(ICER)。在策略 B 中,FP 上的黄斑出血或微动脉瘤被去除作为可能 DME 的替代标志物。策略 C 在可疑病例中使用最佳矫正视力(BCVA)而不是习惯/针孔 VA,并在 OCT 上增加中央视网膜厚度(CST)>290 μm 作为可能 DME 的确认标志物。策略 D 在所有受试者中使用 CST >290 μm OCT 作为疑似 DME 的替代标志物。
我们招募了 2277 名受试者(平均年龄 62.80±11.75 岁,43.7%为男性)。策略 A、B、C 和 D 的敏感度和特异度分别为 40.95%和 86.60%、22.86%和 95.63%、32.38%和 100%和 74.47%和 98.34%。策略 A、B、C 和 D 每获得一个 QALY 的成本(美元)分别为 7447.50、8428.70、5992.30 和 4113.50。
当前方案的高假阳性率导致不必要的转诊,这给患者带来不便,也给社会带来成本。将普遍 OCT 筛查 DME 纳入筛查方案可以将假阳性结果减少八倍,同时提高敏感性和长期成本效益。